| Literature DB >> 23091734 |
Markus Quante1, Christoph Benckert, Armin Thelen, Sven Jonas.
Abstract
Because of increasing waiting-list mortality, the MELD (Model for End-Stage Liver Disease) allocation system was implemented within most countries of the Eurotransplant area on December 16, 2006. Five years have now passed, and we review in this paper the effects of the MELD-based allocation upon the waiting list for liver transplantation, on peri-operative management and on postoperative outcome. Giving priority to sicker patients on the waiting list has resulted in a significant increase in mean MELD score at the time of organ allocation. Consequently, there has also been a significant reduction in waiting-list mortality. However, in Germany a worsening in postoperative outcome, mainly in the group of high-MELD recipients (≥30 points), has been reported. This paper presents comprehensive results following liver transplantation within the MELD era. Especially for the group of high-risk recipients, risk factors for impaired survival are presented and discussed.Entities:
Year: 2012 PMID: 23091734 PMCID: PMC3467768 DOI: 10.1155/2012/264015
Source DB: PubMed Journal: Int J Hepatol
Standard MELD exceptions in Germany and their adjusted MELD score or adjusted 3-months-mortality, respectively [3].
| Disease | Initial match MELD/adjusted 3-month mortality |
|---|---|
| Hepatocellular carcinoma (HCC) | 15% |
| Hepatoblastoma | MELD 30 |
| Polycystic liver disease | 10% |
| Hyperoxaluria type 1 | 10% |
| Persisting dysfunction following OLT | Current lab MELD |
| Cystic fibrosis | 10% |
| Familial amyloid polyneuropathy (FAP) | 15% |
| Hepatopulmonary syndrome | 15% |
| Portopulmonary hypertension (POPH) | 25% |
| Urea cycle disorders | MELD 30 |
| Morbus Osler | 15% |
| Hepatic epithelioid hemangioendothelioma (HEHE) | 15% |
| Biliary sepsis/secondary sclerosing cholangitis (SSC) | Current lab MELD |
| Primary sclerosing cholangitis (PSC) | 15% |
| Cholangiocarcinoma | 10% |